TalkMed Group Limited

Equities

5G3

SG2G61000003

Healthcare Facilities & Services

Market Closed - Singapore S.E. Other stock markets 02:16:29 05/07/2024 BST			5-day change	1st Jan Change
0.4 ^SGD	0.00%		+1.27%	+5.26%

06-19	TalkMed Continues Preliminary Discussions Over Acquisition	MT
05-23	TalkMed’s Subsidiary Enters Sale and Purchase Agreement to Dispose Shares in Unit	MT

110,400,000 shares of TalkMed Group Limited's Ordinary Shares are subject to a Lock-Up Agreement Ending on 30-JAN-2016.

January 29, 2016

110,400,000 shares of TalkMed Group Limited's Ordinary Shares are subject to a Lock-Up Agreement Ending on 30-JAN-2016. These shares will be under lockup for 730 days starting from 30-JAN-2014 to 30-JAN-2016.

Latest news about TalkMed Group Limited

TalkMed Continues Preliminary Discussions Over Acquisition	06-19	MT
TalkMed’s Subsidiary Enters Sale and Purchase Agreement to Dispose Shares in Unit	05-23	MT
TalkMed in Preliminary Acquisition Talks	05-17	MT
TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023	04-18	CI
TalkMed Reaches Final Settlement in Mediation Related to Claims in Stem Med Stake Disposal	04-17	MT
TalkMed Group Awards 1.1 Million New Shares	03-14	MT
TalkMed's H2 Attributable Profit Falls on Wider Impairment Loss	02-21	MT
Talkmed Group Limited Proposes Tax Exempt (One-Tier) Final Dividend for the Financial Year Ended 31 December 2023, Payable on 10 May 2024	02-20	CI
TalkMed Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-20	CI
TalkMed Group Grants Nearly 8 Million Share Awards Under Performance Share Plan	12-20	MT
TalkMed Group Limited Announces Management Changes	11-10	CI
TalkMed Group Limited Announces Re-Designation of Leong Ching Ching from Non-Executive Director to Independent Non-Executive Director and Appoints as Chairman of the Remuneration Committee, Effective January 1, 2024	11-10	CI
TalkMed Group Limited Announces Re-Designation of S. Chandra Das from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024	11-10	CI
TalkMed Group Limited Announces Re-Designation of Sitoh Yih Pin from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024	11-10	CI
Talkmed Group Limited Appoints Khoo Kei Siong as Alternate Director to Ang Peng Tiam, Effective January 1, 2024	11-10	CI
TalkMed Group Limited Appoints Dr Tan Khai Tong as Independent Non-Executive Director, Member of the Remuneration Committee, Effective January 1, 2024	11-10	CI
TalkMed Group Limited Appoints Peter Sim Swee Yam as Independent Non-Executive Director, Chairman of the Nominating Committee, Member of the Audit and Risk Committee, Effective January 1, 2024	11-10	CI
TalkMed Group Limited Appoints Lam Kok Shang as Independent Non-Executive Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee, Effective January 1, 2024	11-10	CI
TalkMed Group Issues New Shares Upon Vesting of Share Awards	19/10/23	MT
TalkMed Group Issues New Shares Upon Vesting of Share Awards	17/10/23	MT
Singapore Stocks Track Global Gains to Close Higher; Delfi Shares Jump 3% on Higher H1 Profit, Revenue	08/08/23	MT
TalkMed Group's Attributable Profit Zooms 18% in H1	08/08/23	MT
TalkMed Group Limited Declares Tax Exempt (One-Tier) Interim Dividend for the Financial Year Ending 31 December 2023, Payable on 22 August 2023	07/08/23	CI
TalkMed Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	07/08/23	CI
TalkMed Group Establishes New Subsidiary for Cell, Gene Therapy	07/07/23	MT

Chart TalkMed Group Limited

Duration

Period

More charts

Company Profile

TalkMed Group Limited is a Singapore-based investment holding company. The Company provides medical oncology and palliative care healthcare services. Its segments include Oncology services, and Cellular and gene therapy related products and services. Oncology services segment comprises medical oncology services targeting various cancers, such as breast cancer, colon cancer, lung cancer, liver, biliary and pancreatic cancers, gastro-intestinal cancers, head and neck cancers, leukemia, hematology malignancies and brain cancer. It includes Parkway Cancer Centre, Thu Cuc International General Hospital. The Cellular and gene therapy related products and services segment includes provision of goods and services related to cellular and gene therapy through its subsidiaries, CellVec Pte. Ltd., and BioCell Innovations Pte. Ltd. The Company, through the Parkway Cancer Centre (PCC)-vehicle, offers a support system to cater to the psychosocial needs of its patients and their families.

Sector

Healthcare Facilities & Services

Calendar

29/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
TALKMED GROUP LIMITED	+5.26%	393M
HCA HEALTHCARE, INC.	+18.33%	83.89B
CVS HEALTH CORPORATION	-28.29%	71.08B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.99%	26.77B
FRESENIUS SE & CO. KGAA	+3.67%	17.74B
LABCORP HOLDINGS INC.	-9.99%	17.24B
QUEST DIAGNOSTICS INCORPORATED	+1.86%	15.6B
NATERA, INC.	+79.98%	13.84B
PURE HEALTH HOLDING	-25.09%	12.92B
TENET HEALTHCARE CORPORATION	+74.41%	12.87B

Other Healthcare Facilities & Services